Literature DB >> 27416039

Age Disparities in the Use of Steroid-sparing Therapy for Inflammatory Bowel Disease.

Shail M Govani1, Wyndy L Wiitala, Ryan W Stidham, Sameer D Saini, Jason K Hou, Linda A Feagins, Jeremy B Sussman, Peter D R Higgins, Akbar K Waljee.   

Abstract

BACKGROUND: Corticosteroids are effective rescue therapies for patients with inflammatory bowel disease (IBD), but have significant side effects, which may be amplified in the growing population of elderly patients with IBD. We aimed to compare the use of steroids and steroid-sparing therapies (immunomodulators and biologics) and rates of complications among elderly (≥65) and younger patients in a national cohort of veterans with IBD.
METHODS: We used national Veterans Health Administrative data to conduct a retrospective study of veterans with IBD between 2002 and 2010. Medications and the incidence of complications were obtained from the Veterans Health Administrative Decision Support Systems. Multivariate logistic regression accounting for facility-level clustering was used to identify predictors of use of steroid-sparing medications.
RESULTS: We identified 30,456 veterans with IBD. Of these, 94% were men and 40% were more than 65, and 32% were given steroids. Elderly veterans were less likely to receive steroids (23.8% versus 38.3%, P < 0.001) and were less likely to be prescribed steroid-sparing medications (25.5% versus 46.9%, respectively, P < 0.001). In multivariate analysis controlling for sex, age <65 (odds ratio, 2.19; 95% CI, 1.54-3.11) and gastroenterology care (odds ratio, 8.42; 95% CI, 6.18-11.47) were associated with initiation of steroid-sparing medications. After starting steroids, fracture rates increased in the elderly patients with IBD, whereas increases in venous thromboembolism and infections after starting steroids affected both age groups.
CONCLUSIONS: Elderly veterans are less likely to receive steroids and steroid-sparing medications than younger veterans; elderly patients exposed to steroids were more likely to have fractures than the younger population.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27416039      PMCID: PMC4956567          DOI: 10.1097/MIB.0000000000000817

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  18 in total

1.  IBD in the elderly population: results from a population-based study in Western Hungary, 1977-2008.

Authors:  Peter Laszlo Lakatos; Gyula David; Tunde Pandur; Zsuzsanna Erdelyi; Gabor Mester; Mihaly Balogh; Istvan Szipocs; Csaba Molnar; Erzsebet Komaromi; Lajos S Kiss; Laszlo Lakatos
Journal:  J Crohns Colitis       Date:  2010-09-15       Impact factor: 9.071

Review 2.  Glucocorticoid-induced osteoporosis: pathogenesis and management.

Authors:  B P Lukert; L G Raisz
Journal:  Ann Intern Med       Date:  1990-03-01       Impact factor: 25.391

Review 3.  Inflammatory bowel disease in the elderly.

Authors:  Syed Wasif Hussain; Darrell S Pardi
Journal:  Drugs Aging       Date:  2010-08-01       Impact factor: 3.923

4.  Inflammatory bowel disease of the elderly: a wake-up call.

Authors:  Seymour Katz; Richard Feldstein
Journal:  Gastroenterol Hepatol (N Y)       Date:  2008-05

5.  Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease.

Authors:  Mario Cottone; Anna Kohn; Marco Daperno; Alessandro Armuzzi; Luisa Guidi; Renata D'Inca; Fabrizio Bossa; Erika Angelucci; Livia Biancone; Paolo Gionchetti; Sandro Ardizzone; Claudio Papi; Walter Fries; Silvio Danese; Gabriele Riegler; Maria Cappello; Fabiana Castiglione; Vito Annese; Ambrogio Orlando
Journal:  Clin Gastroenterol Hepatol       Date:  2010-10-15       Impact factor: 11.382

6.  Accuracy of diagnostic codes for identifying patients with ulcerative colitis and Crohn's disease in the Veterans Affairs Health Care System.

Authors:  Jason K Hou; Mimi Tan; Ryan W Stidham; John Colozzi; Devon Adams; Hashem El-Serag; Akbar K Waljee
Journal:  Dig Dis Sci       Date:  2014-05-10       Impact factor: 3.199

Review 7.  An update on the epidemiology of inflammatory bowel disease in Asia.

Authors:  Kelvin T Thia; Edward V Loftus; William J Sandborn; Suk-Kyun Yang
Journal:  Am J Gastroenterol       Date:  2008-12       Impact factor: 10.864

8.  Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study.

Authors:  Nabeel Khan; Ali M Abbas; Gary R Lichtenstein; Edward V Loftus; Lydia A Bazzano
Journal:  Gastroenterology       Date:  2013-07-25       Impact factor: 22.682

Review 9.  Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease.

Authors:  Javier P Gisbert; María Chaparro
Journal:  Am J Gastroenterol       Date:  2013-06-11       Impact factor: 10.864

Review 10.  Guidelines for the management of inflammatory bowel disease in adults.

Authors:  Craig Mowat; Andrew Cole; Al Windsor; Tariq Ahmad; Ian Arnott; Richard Driscoll; Sally Mitton; Tim Orchard; Matt Rutter; Lisa Younge; Charlie Lees; Gwo-Tzer Ho; Jack Satsangi; Stuart Bloom
Journal:  Gut       Date:  2011-05       Impact factor: 23.059

View more
  13 in total

1.  Early combined immunosuppression may be effective and safe in older patients with Crohn's disease: post hoc analysis of REACT.

Authors:  Siddharth Singh; Larry W Stitt; Guangyong Zou; Reena Khanna; Parambir S Dulai; William J Sandborn; Brian G Feagan; Vipul Jairath
Journal:  Aliment Pharmacol Ther       Date:  2019-03-19       Impact factor: 8.171

Review 2.  IBD in the Elderly: Management Challenges and Therapeutic Considerations.

Authors:  Vivy Tran; Berkeley N Limketkai; Jenny S Sauk
Journal:  Curr Gastroenterol Rep       Date:  2019-11-27

3.  Clinical Considerations Regarding the Use of Thiopurines in Older Patients with Inflammatory Bowel Disease.

Authors:  Margalida Calafat; Míriam Mañosa; Fiorella Cañete; Eugeni Domènech
Journal:  Drugs Aging       Date:  2021-01-13       Impact factor: 3.923

4.  Advanced age adversely affects chronic rhinosinusitis surgical outcomes.

Authors:  Kristen L Yancey; Anne S Lowery; Rakesh K Chandra; Naweed I Chowdhury; Justin H Turner
Journal:  Int Forum Allergy Rhinol       Date:  2019-08-27       Impact factor: 3.858

5.  Implications of Prostate Cancer Treatment in Men With Inflammatory Bowel Disease.

Authors:  Peter S Kirk; Shail Govani; Tudor Borza; Brent K Hollenbeck; Jennifer Davis; Dean Shumway; Akbar K Waljee; Ted A Skolarus
Journal:  Urology       Date:  2017-02-03       Impact factor: 2.649

Review 6.  Management of Inflammatory Bowel Diseases in Special Populations: Obese, Old, or Obstetric.

Authors:  Siddharth Singh; Sherman Picardo; Cynthia H Seow
Journal:  Clin Gastroenterol Hepatol       Date:  2019-11-08       Impact factor: 11.382

Review 7.  Elderly patients with inflammatory bowel disease: Updated review of the therapeutic landscape.

Authors:  Jean-Frédéric LeBlanc; Daniel Wiseman; Peter L Lakatos; Talat Bessissow
Journal:  World J Gastroenterol       Date:  2019-08-14       Impact factor: 5.742

8.  Association of Anti-Tumor Necrosis Factor Therapy With Mortality Among Veterans With Inflammatory Bowel Disease.

Authors:  Shirley Cohen-Mekelburg; Beth I Wallace; Tony Van; Wyndy L Wiitala; Shail M Govani; Jennifer Burns; Rachel Lipson; Huifeng Yun; Jason Hou; James D Lewis; Jason A Dominitz; Akbar K Waljee
Journal:  JAMA Netw Open       Date:  2021-03-01

9.  The 5Ms of Geriatrics in Gastroenterology: The Path to Creating Age-Friendly Care for Older Adults With Inflammatory Bowel Diseases and Cirrhosis.

Authors:  Bharati Kochar; Nneka N Ufere; Christine S Ritchie; Jennifer C Lai
Journal:  Clin Transl Gastroenterol       Date:  2022-01-12       Impact factor: 4.396

Review 10.  Orphan patients with inflammatory bowel disease - when we treat beyond evidence.

Authors:  Giuseppe Privitera; Daniela Pugliese; Loris Riccardo Lopetuso; Franco Scaldaferri; Alfredo Papa; Gian Lodovico Rapaccini; Antonio Gasbarrini; Alessandro Armuzzi
Journal:  World J Gastroenterol       Date:  2021-12-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.